UIA
AUTL

Ulland Investment Advisors’s Autolus Therapeutics AUTL Stock Holding History

Ulland Investment Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,000
Closed -$2K – 203
2023
Q3 		$2K Hold
1,000
– – ﹤0.01% 197
2023
Q2 		$2K Hold
1,000
– – ﹤0.01% 199
2023
Q1 		$2K Hold
1,000
– – ﹤0.01% 188
2022
Q4 		$2K Hold
1,000
– – ﹤0.01% 194
2022
Q3 		$2K Hold
1,000
– – ﹤0.01% 200
2022
Q2 		$3K Hold
1,000
– – ﹤0.01% 224
2022
Q1 		$4K Hold
1,000
– – ﹤0.01% 233
2021
Q4 		$5K Buy
+1,000
New +$6K ﹤0.01% 189

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ulland Investment Advisors's AUTL Position: Q4 2023 in Review

Ulland Investment Advisors sold out of Autolus Therapeutics (AUTL) in Q4 2023, closing a stake of 1,000 shares — an estimated $2K sold.

Ulland Investment Advisors first reported a position in AUTL in Q4 2021 and held it in 8 quarters. The position peaked at $5K in Q4 2021. 99 funds tracked by Wall St. Rank hold AUTL as of Q4 2023.

  • Ulland Investment Advisors reported no remaining Autolus Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Ulland Investment Advisors sold 1,000 Autolus Therapeutics shares in Q4 2023, an estimated $2K.
  • Ulland Investment Advisors first reported a position in Autolus Therapeutics in Q4 2021 and held it in 8 quarters.
  • Ulland Investment Advisors's Autolus Therapeutics position peaked at $5K in Q4 2021.
  • 99 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2023.

Based on Ulland Investment Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.